Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New vaccine shows promise for COPD patients at risk for pneumonia

10.09.2009
A new vaccine against pneumonia may offer better protection from chronic obstructive pulmonary disease (COPD) patients than the currently accepted vaccine, according to recent research that will be published in the September 15 issue of the American Journal of the Respiratory and Critical Care Journal, a publication of the American Thoracic Society.

Because pneumonia disproportionately affects patients with COPD and frequently causes exacerbations, the Centers for Disease Control currently recommend that all adults with COPD receive the 23-valent pneumococcal polysaccharide vaccination (PPSV23). However, the efficacy of PPSV23 is not well established in the COPD patient population.

"Reasonable effectiveness for this vaccine has been demonstrated in cohort studies in adults with lung disease," said Mark Dransfield, M.D. of the University of Alabama at Birmingham and lead author of the study. "[However,] debate remains about its immunogenicity and effectiveness in COPD."

Dr. Dransfield and colleagues sought to determine the efficacy of a newer type of vaccine, PCV7, a protein conjugate vaccine, which attaches a weak antigen (in this case, the pneumococcal polysaccharide antigen) to a stronger antigen (the diphtheria toxin) in the hope that the stronger antigen with provoke a more forceful defense from the immune system.

"Conjugated vaccines were originally intended for young children who respond poorly to polysaccharide antigens," said Dr. Dransfield. "We wanted to see whether they could have a similar effect in the COPD patient population in whom immune responses may also be blunted."

Results of the randomized open label trial of 120 adults with moderate to severe COPD showed that, while both the PPSV23 vaccine and the PCV7 vaccine were well-tolerated, the PCV7 vaccine produced superior immune responses on several measures of immunogenicity. Among patients randomized to take the PCV7 vaccine, the fraction exhibiting a twofold increase in serotype-specific IgG antibodies was higher in five of the seven serotypes tested. Blood drawn from patients who had received the PCV7 vaccine was also more effective at killing pneumococci in six of seven serotypes tested one month after vaccination.

"We have shown that PCV7 induces a superior immune response to PPSV23 in COPD at one month post-vaccination," concluded Dr. Dransfield. "Both vaccines elicit responses comparable to those previous observed in health elderly patients." Older age and prior vaccination with PPSV23 dampened the efficacy of the PCV7 vaccine, however.

A vaccine in development that contains the capsule of 13 pneumococcal serotypes, called PCV13 (compared to PCV7 which has seven) is hoped to expand the coverage of the vaccine.

"We hope that future research will confirm the superior immunogenicity of PCV13 in COPD," he added. "We also want to determine the relative duration of the immune response following PPSV23 and conjugate vaccination and to identify the immunologic correlates of protection against both invasive and non-invasive pneumococcal disease. We believe our data provide the rationale for further study of the clinical efficacy of protein-conjugate pneumococcal vaccines in the high risk COPD population."

Keely Savoie | EurekAlert!
Further information:
http://www.thoracic.org

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>